drugset / Trial / NCT05573724

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

NCT05573724

Phase 1 Completed 16 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open-label, multi-centre drug-drug interaction (DDI) study of AZD5305 administered orally in patients with advanced solid tumours.

Timeline

Start
2022-11-07
Primary completion
2023-04-17
Completion
2024-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject Saruparib Small molecule Oral